830 related articles for article (PubMed ID: 29097108)
1. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Steger GG; Egle D; Bartsch R; Pfeiler G; Petru E; Greil R; Helfgott R; Marth C; Öhler L; Hubalek M; Lang A; Tinchon C; Haslbauer F; Redl A; Hock K; Hennebelle M; Mraz B; Gnant M
Breast; 2020 Apr; 50():64-70. PubMed ID: 32062536
[TBL] [Abstract][Full Text] [Related]
4. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
[TBL] [Abstract][Full Text] [Related]
8. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
Royce M; Bachelot T; Villanueva C; Özgüroglu M; Azevedo SJ; Cruz FM; Debled M; Hegg R; Toyama T; Falkson C; Jeong J; Srimuninnimit V; Gradishar WJ; Arce C; Ridolfi A; Lin C; Cardoso F
JAMA Oncol; 2018 Jul; 4(7):977-984. PubMed ID: 29566104
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
10. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
[TBL] [Abstract][Full Text] [Related]
11. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
12. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
[TBL] [Abstract][Full Text] [Related]
13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
14. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Ciruelos E; Vidal M; Martínez de Dueñas E; Martínez-Jáñez N; Fernández Y; García-Sáenz JA; Murillo L; Carabantes F; Beliera A; Fonseca R; Gavilá J
Clin Transl Oncol; 2018 Jun; 20(6):753-760. PubMed ID: 29116433
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Toi M; Shao Z; Hurvitz S; Tseng LM; Zhang Q; Shen K; Liu D; Feng J; Xu B; Wang X; Lee KS; Ng TY; Ridolfi A; Noel-Baron F; Ringeisen F; Jiang Z
Breast Cancer Res; 2017 Apr; 19(1):47. PubMed ID: 28399902
[TBL] [Abstract][Full Text] [Related]
17. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Janni W; Alba E; Bachelot T; Diab S; Gil-Gil M; Beck TJ; Ryvo L; Lopez R; Tsai M; Esteva FJ; Auñón PZ; Kral Z; Ward P; Richards P; Pluard TJ; Sutradhar S; Miller M; Campone M
Breast Cancer Res Treat; 2018 Jun; 169(3):469-479. PubMed ID: 29404806
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
19. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR
Brufsky A; Mitra D; Davis KL; Nagar SP; McRoy L; Cotter MJ; Stearns V
Clin Breast Cancer; 2019 Oct; 19(5):317-325.e4. PubMed ID: 31104984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
